Results 81 to 90 of about 479 (110)

Stability-Indicating Assay of Novel 5-(Hydroxamic acid)methyl Oxazolidinones with 5-Lipooxygenase Inhibitory Activity. [PDF]

Pharmaceuticals (Basel)
Al-Mutairi HM, Phillips OA, Al-Tannak NF.   +2 more
europepmc   +1 more source

Research overview-2025: integrating scientific progress to accelerate global tuberculosis elimination. [PDF]

Front Tuberc
Moonan PK, Holtz TH.
europepmc   +1 more source

panTB-HM: a clinical trial of a pan-TB regimen targeting both host and microbe

Mudzengi D, Mashatole S, Xiang Q, Adrion C, Glover N, Ngwanto T, Mdluli J, Boniface S, Rassool M, Paramo L, Svensson E, Fasanmi A, Angelo S, Moyo M, Marx C, Khosa C, Mofokeng N, Lalashowi J, Nacy C, Charalambous S, Fumane E, Maphossa V, Beattie T, Brumskine W, Venter C, Mapamba D, Heinrich N, Rajaram S, Kooverjee S, Nell M, Easton A, Foraida S, Ntinginya N, Wallis R.   +33 more
europepmc   +1 more source

Drug-Resistant Tuberculous Meningitis (DR-TBM) in a Low-Incidence Setting: Two Cases and an Evidence Review Highlighting Key Advances and Knowledge Gaps in Clinical Management. [PDF]

Open Forum Infect Dis
Boschung KF, Wong PHP, Werry D, Sekirov I, Turvey SL, Cook VJ, Johnston J, Connors WJA.   +7 more
europepmc   +1 more source

Predicting tuberculosis drug efficacy in preclinical and clinical models from <i>in vitro</i> data. [PDF]

iScience
Goh JJN, Patel A, Ngara B, van Wijk RC, Strydom N, Wang Q, Van N, Washington TM, Nuermberger EL, Aldridge BB, Roubert C, Sarathy J, Dartois V, Savic RM.   +13 more
europepmc   +1 more source

Deciphering linezolid-induced hematologic toxicity: Targeting TOP2A and TOP2B via its primary metabolite PNU142586. [PDF]

Sci Adv
Thu VTA, Nhu NQ, Anh NTV, Lim SA, Seong HJ, Md Rasheduzzaman J, Kim U, Cho HS, Soedarsono S, Shin JG, Cho YS.   +10 more
europepmc   +1 more source

Therapeutic developments for tuberculosis and nontuberculous mycobacterial lung disease. [PDF]

Nat Rev Drug Discov
Dartois V, Dick T.
europepmc   +1 more source

Contribution of direct InhA inhibitors to novel drug regimens in a mouse model of tuberculosis. [PDF]

Antimicrob Agents Chemother
Encinas L, Li S-Y, Rullas-Trincado J, Tasneen R, Tyagi S, Soni H, Garcia-Perez A, Lee J, González Del Río R, De Mercado J, Sousa V, Sosič I, Gobec S, Mendoza-Losana A, Converse PJ, Mdluli K, Fotouhi N, Barros-Aguirre D, Nuermberger EL.   +18 more
europepmc   +1 more source

Large-scale testing of antimicrobial lethality at single-cell resolution predicts mycobacterial infection outcomes. [PDF]

Nat Microbiol
Jovanovic A, Bright FK, Sadeghi A, Wicki B, Caño Muñiz SE, Giannini GC, Toprak S, Sauteur L, Rodoni A, Wüst A, Lupien A, Borrell S, Grogono DM, Wheeler NE, Dehio P, Nemeth J, Pargger H, Thomson R, Bell SC, Gagneux S, Bryant JM, Peng T, Diacon AH, Floto RA, Abanto M, Boeck L.   +25 more
europepmc   +1 more source

Durable three-year outcomes and persistent neuropathy following nine-month all-oral regimens for rifampicin-resistant tuberculosis: a multicentre cohort study in China. [PDF]

BMC Infect Dis
Fu L, Shi H, Sun F, Wang W, Zhang P, Yang Q, Cai Y, Zhang X, Liang H, Wang Z, Xiong J, Chen X, Zhang W, Deng G.   +13 more
europepmc   +1 more source